ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: 1572 • 2014 ACR/ARHP Annual Meeting

    Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial

    Christopher J. Edwards1, Jacob A. Aelion2, Adewale O. Adebajo3, Alan Kivitz4, Paul Bird5, ChiaChi Hu6, Randall M. Stevens6 and Alvin Wells7, 1University Hospital Southampton, Southampton, United Kingdom, 2West Tennessee Research Institute, Jackson, TN, 3University of Sheffield, Sheffield, United Kingdom, 4Altoona Arthritis & Osteoporosis Center, Duncansville, PA, 5Combined Rheumatology Practice, Kogarah, Australia, 6Celgene Corporation, Warren, NJ, 7Rheumatology & Immunotherapy Center, Franklin, WI

    Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…
  • Abstract Number: 537 • 2014 ACR/ARHP Annual Meeting

    Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial

    Alice B. Gottlieb1, Philip J. Mease2, Iain B. McInnes3, Bruce Kirkham4, Arthur Kavanaugh5, Proton Rahman6, Peter Nash7, Luminita Pricop8, Jiacheng Yuan9, Hanno Richards10 and Shephard Mpofu11, 1Tufts Medical Center, Boston, MA, 2Swedish Medical Center and University of Washington, Seattle, WA, 3University of Glasgow, Glasgow, United Kingdom, 4Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 5UCSD School of Medicine, La Jolla, CA, 6Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 7University of Queensland, Brisbane, Australia, 8Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, 11Novartis Pharma AG, Basel, Switzerland

    Background/Purpose Reducing the burden of skin manifestations of psoriatic arthritis (PsA) is an important aspect of disease management. Secukinumab, a human anti–IL-17A monoclonal antibody, has…
  • Abstract Number: 816 • 2013 ACR/ARHP Annual Meeting

    Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials

    Dafna D. Gladman1, Philip J. Mease2, Arthur Kavanaugh3, Adewale O. Adebajo4, Juan J. Gomez-Reino5, Jürgen Wollenhaupt6, Maurizio Cutolo7, Georg Schett8, Eric Lespessailles9, Kamal Shah10, ChiaChi Hu10, Randall M. Stevens10, Christopher J. Edwards11 and Charles A. Birbara12, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 3University of California San Diego, San Diego, CA, 4Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, 5Hospital Clinico Universitario, Santiago, Spain, 6Schön Klinik Hamburg-Eilbek, Hamburg, Germany, 7University of Genova, Genova, Italy, 8Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 9University of Orléans, Orléans, France, 10Celgene Corporation, Warren, NJ, 11University of Southampton, Southampton, United Kingdom, 12University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…
  • Abstract Number: L4 • 2013 ACR/ARHP Annual Meeting

    Apremilast in the Treatment of DMARD-Naïve Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4)

    Alvin F. Wells1, Christopher J. Edwards2, Adewale O. Adebajo3, Alan J. Kivitz4, Paul Bird5, Kamal Shah6, ChiaChi Hu6, Randall M. Stevens6 and Jacob A. Aelion7, 1Rheumatology and Immunotherapy Center, Franklin, WI, 2University Hospital Southampton, Southampton, United Kingdom, 3University of Sheffield, Sheffield, United Kingdom, 4Altoona Center for Clinical Research, Duncansville, PA, 5Combined Rheumatology Practice, Sydney, Australia, 6Celgene Corporation, Warren, NJ, 7West Tennessee Research Institute, Jackson, TN

    Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 4 compared APR with placebo (PBO) in DMARD-naïve patients (pts) with…
  • Abstract Number: 818 • 2013 ACR/ARHP Annual Meeting

    HLA-B*0801 Is Strongly Associated With Asymmetrical Sacroiliitis and HLA-B*27 With Symmetrical Involvement In Psoriatic Arthritis: Results Of a Long-Term Follow-Up Study Examining Clinical and Genetic Predictors Of Radiographic Sacroiliitis

    Muhammad Haroon1, Agnes Szentpetery2, Phil Gallagher3, Robert Winchester4 and Oliver FitzGerald1, 1Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 3Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 4Dept of Medicine & Pathology, Columbia University, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) is characterised by involvement of both the appendicular and axial skeleton.  Little is known about the clinical predictors of sacroiliitis (SI),…
  • Abstract Number: L10 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 2-Year Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

    Arthur Kavanaugh1, Luis Puig2, Alice B. Gottlieb3, Christopher T. Ritchlin4, Shu Li5, Yuhua Wang5, Alan Mendelsohn6, Michael Song5, Proton Rahman7 and Iain B. McInnes8, 1UCSD School of Medicine, La Jolla, CA, 2Universitat Autònoma de Barcelona, Barcelona, Spain, 3Tufts Medical Center, Boston, MA, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5Janssen Research & Development, LLC., Spring House, PA, 6Immunology, Janssen Research & Development, LLC, Spring House, PA, 7Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 8University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: To evaluate long-term clinical/radiographic efficacy of subcutaneous UST 45/90 mg in patients with active psoriatic arthritis (PsA) through wk108 of the PSUMMIT 1 trial.…
  • Abstract Number: 2478 • 2013 ACR/ARHP Annual Meeting

    Clinical Characteristics Of Patients With Early Spondyloarthritis. Results From a Specialized Consultation In a Clinical Hospital

    Juan Jose Aznar Sánchez, Eugenio Chamizo Carmona, Adela Gallego Flores, Raul Veroz Gonzalez and Tamara Libertad Rodriguez Araya, Rheumatology, Hospital de Mérida, Mérida, Spain

    Background/Purpose: The classification criteria for spondyloarthritis (SpA) intend to identify patients with this disease from the initial stages.  The nonspecific characteristics,  symptoms, signs, and additional…
  • Abstract Number: 528 • 2013 ACR/ARHP Annual Meeting

    Upregulated Th17 and Innate Pathways Are More Characteristic Of The Skin Than The Synovium In Psoriatic Arthritis

    Jennifer Belasco1, Hiroshi Mitsui1, Mayte Suarez-Farinas1, James S. Louie2, N. Wei3, Nicholas Gulati1 and James G. Krueger1, 1Krueger Laboratory, The Rockefeller University, New York, NY, 2Rheumatology, UCLA School of Medicine, Los Angeles, CA, 3Arthritis Treatment Center, Frederick, MD

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. There is little understanding of the relative levels of cytokines and chemokines between…
  • Abstract Number: 2486 • 2013 ACR/ARHP Annual Meeting

    Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers

    Carina M F Gomes1, Maria Teresa Terreri2, Maria Isabel Pinto3, Karen Oseki3, Fernanda Spina4 and Marcelo M. Pinheiro5, 1Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, 2Pediatrics, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, 3Pediatrics, Universidade Federal de São Paulo, Sao Paulo, Brazil, 4Rheumatology Division, Universidade Federal de São Paulo Unifesp/EPM, Brazil, Universidade Federal de São Paulo, Sao Paulo, Brazil, 5Brazilian Registry of Spondyloarthritis, São Paulo, Brazil

    Background/Purpose: About 5% of the Brazilian population has some chronic inflammatory arthropathy (CIA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PA) and juvenile…
  • Abstract Number: 344 • 2013 ACR/ARHP Annual Meeting

    Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis

    Muhammad Haroon1, Phil Gallagher2 and Oliver FitzGerald1, 1Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Rheumatology, St. Vincent's University Hospital, Dublin, Ireland

    Background/Purpose: Arthritis mutilans (AM), a severe form of psoriatic arthritis (PsA), is characterised clinically by digital shortening resulting from osteolysis and/or erosions. It is still…
  • Abstract Number: 2443 • 2013 ACR/ARHP Annual Meeting

    Prevalence Of Coronary Heart Disease In Spondyloarthopathies  may Be Increased Due To Higher Prevalence Of Risk Factors As Well As The Disease Itself- A Retrospective Analysis At Single VA Medical Center

    Trayton Mains1 and Vikas Majithia2, 1University of Mississippi Medical Center, Jackson, MS, 2G.V. "Sonny" Montogomery VA Medical Center, Jackson, MS

    Background/Purpose: An increased prevalence of cardiovascular disease (CVD) and coronary heart disease (CHD) has been reported in patients with spondyloarthritides (SpA). This study investigated the…
  • Abstract Number: 348 • 2013 ACR/ARHP Annual Meeting

    Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials

    Philip J. Mease1, Arthur Kavanaugh2, Adewale O. Adebajo3, Juan J. Gomez-Reino4, Jürgen Wollenhaupt5, Dafna D. Gladman6, Maurizio Cutolo7, Georg Schett8, Eric Lespessailles9, Kamal Shah10, ChiaChi Hu10, Randall M. Stevens10, Christopher J. Edwards11 and Charles A. Birbara12, 1Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 2University of California San Diego, San Diego, CA, 3Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, 4Hospital Clinico Universitario, Santiago, Spain, 5Schön Klinik Hamburg-Eilbek, Hamburg, Germany, 6University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 7University of Genova, Genova, Italy, 8Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 9University of Orléans, Orléans, France, 10Celgene Corporation, Warren, NJ, 11NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 12University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy and…
  • Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting

    Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions:  Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab

    Rene Westhovens1, Clifton O. Bingham III2, Michael E. Weinblatt3, Roy Fleischmann4, Edward C. Keystone5, Elizabeth C. Hsia6, Benjamin Hsu6, Lilianne Kim6, Surekha Mudivarthy6, Michael Mack7, Neil Goldstein6, Jürgen Braun8, Arthur Kavanaugh9, Alan M. Mendelsohn10 and Jonathan Kay11, 1Rheumatology, University Hospital KU Leuven, Leuven, Belgium, 2Rheumatology, Johns Hopkins University, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4University of Texas Southwestern Medical Center, Dallas, TX, 5Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 6Janssen Research & Development, LLC., Spring House, PA, 7Biostatistics, Janssen Research & Development, LLC., Spring House, PA, 8PsAID taskforce, EULAR, Zurich, Switzerland, 9University of California San Diego, San Diego, CA, 10Immunology, Janssen Research & Development, LLC., Spring House, PA, 11UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA

    Background/Purpose:   To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…
  • Abstract Number: 350 • 2013 ACR/ARHP Annual Meeting

    Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis

    Agnes Szentpetery1, Muhammad Haroon2, Phil Gallagher3, Eric J. Heffernan4 and Oliver FitzGerald2, 1Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 2Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 3Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 4Radiology, St. Vincent's University Hospital, Dublin, Ireland

    Background/Purpose: Structural destruction in peripheral joints may occur over time in both PsA and RA. We previously reported that 47% of early PsA patients treated…
  • Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting

    COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys

    Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland

    Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
  • « Previous Page
  • 1
  • …
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology